| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0597f9c318d2aeca86db94711c516383 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-31
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-73
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-545 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-573
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2809 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2020-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_828e29d8cf832bc75602d9c0bc3acf4c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f95fbfd481aeb5769b13787fe0cadc8b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b71629559c6eb9df62b7165846786cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1aa58e428586363bbdd9c8fa11c9db17 |
| publicationDate |
2021-09-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-202132340-A |
| titleOfInvention |
Methods for treating leukemia |
| abstract |
The present invention relates to treatment methods for leukemia using bispecific antibody constructs that specifically bind to human CD33 and human CD3. In particular, the present invention relates to methods for treating myeloid leukemia, including relapsed/refractory myeloid leukemia, in a patient in need thereof comprising administering to the patient at least one initiation cycle and at least one maintenance cycle of an anti-CD33 x anti-CD3 bispecific antibody construct, wherein each initiation cycle and maintenance cycle comprises administering the bispecific antibody construct according to specific dosage regimens. Pharmaceutical compositions comprising the bispecific antibody constructs for use in the methods are also disclosed. |
| priorityDate |
2019-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |